At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 7, 2026 at 08:35 ET
Abeona Therapeutics appointed Keith A. Goldan to its Board of Directors and as Chair of the Audit Committee, citing his two decades of financial leadership experience in biotech. The move strengthens governance as the company advances its commercial-stage gene therapy operations.
- Keith A. Goldan appointed to Board of Directors effective April 1, 2026
- Goldan also named Chair of the Audit Committee
- Board expanded from nine to ten members
- Goldan is independent under Nasdaq rules
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access